Leerink Partners Remains Bullish on Amicus Therapeutics (FOLD) Following European Commission Approval

Leerink Partners maintained an Outperform rating and $17.00 price target on Amicus Therapeutics (NASDAQ: FOLD) after receiving marketing approval and shipping medicines to Germany. Management noted that the 269 initial amenable mutations for Fabry is not a rigid number and FOLD will diligently assess other mutations to continue expanding the applicability of Galafold in Fabry pt. population.

Analyst Joseph Schwartz commented, "Since receiving a positive opinion from the European Committee for Medicinal Products for Human Use (CHMP) in April, FOLD has both received marketing approval and shipped its first batch of medicines to pts. in Germany. The initial label consists of 269 amenable mutations for Fabry pts. >16 yrs. old. This news is positive as it can expedite mkt. entry into other geographies, both within the EU and outside. Reiterate OP on FOLD."

For an analyst ratings summary and ratings history on Amicus Therapeutics click here. For more ratings news on Amicus Therapeutics click here.

Shares of Amicus Therapeutics closed at $7.06 yesterday.

You May Also Be Interested In

• Citi Upgrades United Microelectronics Corp (2303:TT) (UMC) to Buy 'with limited downside'
• Compass Minerals International (CMP) PT Lowered to $15 at Deutsche Bank
• SL Green Realty (SLG) PT Lowered to $45 at Jefferies